NCT03766646 is a NA clinical trial of Optiflow in Unrecognized Condition, sponsored by University Hospital Southampton NHS Foundation Trust.

Who is sponsoring NCT03766646?

NCT03766646 is sponsored by University Hospital Southampton NHS Foundation Trust.

What drugs are being tested in NCT03766646?

Interventions in NCT03766646: Optiflow.

What condition does NCT03766646 study?

NCT03766646 studies Unrecognized Condition.

Is NCT03766646 still recruiting?

NCT03766646 is currently completed. Last updated 30 October 2020.

Are results published for NCT03766646?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2020-10-30 · How we verify

NCT03766646

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Preoxygenation With Optiflow™ - the Effect of Speech on Lung Oxygenation.

Completed NA Results posted Last updated 30 October 2020

What this trial tests

NA trial testing Optiflow in Unrecognized Condition in 34 participants. Completed in 16 November 2018.

Timeline

18 October 2018

Primary endpoint
16 November 2018

16 November 2018

Quick facts

Lead sponsor	University Hospital Southampton NHS Foundation Trust
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	health services research
Enrollment	34
Start date	18 October 2018
Primary completion	16 November 2018
Estimated completion	16 November 2018
Sites	1 location across United Kingdom

Drugs / interventions tested

Optiflow

Conditions studied

Unrecognized Condition — all drugs for Unrecognized Condition →

Sponsor

University Hospital Southampton NHS Foundation Trust

Who can join

Adults 18 to 65, female only, with Unrecognized Condition. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

End Tidal Oxygen Fraction Primary · At the end of 3 minutes preoxygenation

Oxygen fraction in first expired breath post preoxygenation

Group	Value	95% CI
Speech	43.9	± 15.4
Non-speech	81.9	± 8.3

Sponsor's own description

If a patient speaks during the process of preoxygenation with high-flow nasal oxygen via the Optiflow™ system, is the efficacy reduced as measured by end-tidal lung oxygen content?

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Optiflow

Trials testing the same drug.

NCT02389166 — Optiflow in Sequential Non-Invasive Ventilation · NA · completed

Other recruiting trials for Unrecognized Condition

Currently open trials in the same condition.

NCT06803199 — Effects of LH and FSH on Metabolic Regulation in Cumulus Cells · NA · recruiting
NCT06661967 — Topical Oral Anesthesia Adjuncts in Conventional Intubation on First-Pass Success Rate · NA · recruiting
NCT06243146 — Titration of Inspired Oxygen to Decrease the Incidence of Postoperative Pulmonary Complications · NA · recruiting
NCT06339996 — Male Supplements for Sperm Quality and Aging · NA · recruiting
NCT05873075 — Intravascular Laser Irradiation of Blood Use in Poor Ovarian Responders · NA · active not recruiting

Other University Hospital Southampton NHS Foundation Trust trials

Trials by the same sponsor.

NCT07354971 — IMMUNO-FIT Observational Study · not yet recruiting
NCT07278622 — Virtual Group Prehabilitation Education (Surgery School) Feasibility Trial · NA · recruiting
NCT07357558 — A Qualitative Study Investigating the Lived Experiences and Impact of Reproductive Issues in Adults With Primary Ciliary · recruiting
NCT06851715 — Improving Quality of Life for Teenagers With Asthma · NA · recruiting
NCT07489677 — The Feasibility and Acceptability of a Collaborative Deprescribing Intervention to Reduce Anticholinergic Burden Among H · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03766646 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital Southampton NHS Foundation Trust
Last refreshed: 30 October 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03766646.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing